Vaximm AG, an OSR Company, Updates Term Sheet with BCM Europe to Shorten Exclusivity Period to Three Months

Core Viewpoint - OSR Holdings, Inc. announced an update on the non-binding term sheet between its subsidiary Vaximm AG and BCM Europe AG, shortening the exclusivity period from six months to three months, indicating strong confidence in advancing a definitive global licensing agreement for VXM01, an oral cancer immunotherapy platform [1][2]. Group 1: Agreement Details - The exclusivity period has been reduced to three months, with expectations to finalize a definitive agreement within this timeframe [2]. - Financial terms remain unchanged, including a $20 million upfront payment to Vaximm and up to $815 million in milestone payments [7]. - A blockchain-based royalty participation mechanism utilizing "TAC" tokens is included, which may represent future royalty streams [2][3]. Group 2: Company Statements - Vaximm's CEO, Andreas Niethammer, expressed confidence in BCME's ability to mobilize capital and advance due diligence for VXM01, enhancing the position for a global licensing agreement [2]. - Tim Smith, Head of IR at OSR Holdings, highlighted BCME's commitment and capability to execute the opportunity at an accelerated pace [2]. Group 3: Company Background - OSR Holdings, Inc. is a global healthcare holding company focused on advancing biomedical innovations in healthcare and wellness [4]. - Vaximm AG is a biotechnology company specializing in orally administered T-cell vaccination platforms, with its lead candidate VXM01 targeting VEGFR-2 [5]. - BCM Europe AG is a life sciences investment entity and the largest shareholder of OSR Holdings [6].